Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population

JAMA Network Open

Volumn 2, Issue 12, 2019, Pages E1916526-

  Zidar, David A ^a,b,c   Al Kindi, Sadeer G ^a,c   Liu, Yongmei ^d   Krieger, Nikolas I ^e   Perzynski, Adam T ^f   Osnard, Michael ^c   Nmai, Christopher ^a   Anthony, Donald D ^c,g   Lederman, Michael M ^c   Freeman, Michael L ^c   Bonomo, Robert A ^b   Simon, Daniel I ^a,c   Dalton, Jarrod E ^e,f  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; EPIDEMIOLOGY; FEMALE; HUMAN; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MORTALITY; NUTRITION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; BIOMARKERS; FEMALE; HUMANS; LYMPHOPENIA; MALE; MIDDLE AGED; NUTRITION SURVEYS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 85076114000     PISSN: None     EISSN: 25743805     Source Type: Journal    
DOI: 10.1001/jamanetworkopen.2019.16526     Document Type: Article

References (58)

1. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015;7(310):310rv7. doi:10.1126/scitranslmed.aac7732
2. Haralambieva IH, Painter SD, Kennedy RB, et al. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoS One. 2015;10(3):e0122282. doi:10. 1371/journal.pone.0122282
3. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-1286. doi:10.1056/NEJMoa1113425
4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. doi:10.1038/nature01322
5. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19-20):1267-1284. doi:10.1101/gad.314617.118
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. doi:10. 1016/j.cell.2010.01.025
7. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599-2610. doi:10.1056/NEJMoa040967
8. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368 (21):2004-2013. doi:10.1056/NEJMra1216063
9. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
10. Harrington RA. Targeting inflammation in coronary artery disease. N Engl J Med. 2017;377(12):1197-1198. doi: 10.1056/NEJMe1709904
11. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115-126. doi:10.1056/ NEJM199901143400207
12. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi:10.1016/j.jacc.2012.10.027
13. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833-1842. doi:10. 1016/S0140-6736(17)32247-X
14. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018; 378(21):1976-1986. doi:10.1056/NEJMoa1716078
15. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. doi:10.1056/NEJMoa1200690
16. Horiguchi H, Loftus TJ, Hawkins RB, et al; Sepsis and Critical Illness Research Center Investigators. Innate immunity in the persistent inflammation, immunosuppression, and catabolism syndrome and its implications for therapy. Front Immunol. 2018;9(595):595. doi:10.3389/fimmu.2018.00595
17. Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017;56:221-228. doi:10.1016/j.ijid.2017.01.028
18. Lederman M. Immune success and immune failure in HIV infection: implications for therapeutic intervention. J Acquir Immune Defic Syndr. 2006;42(3):S8-S9. doi:10.1097/01.qai.0000235619.85652.eb
19. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(suppl 6A):9S-16S. doi:10.1016/j.amjmed.2004.02.006
20. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328. doi:10.1016/ S0140-6736(17)32814-3
21. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28(4):671-681, vi. doi:10. 1016/j.hoc.2014.04.005
22. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50. doi:10.1182/blood-2018-06-856500
23. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med. 2005;165(19):2214-2220. doi:10. 1001/archinte.165.19.2214
24. Sullivan P. Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection. J Infect Dis. 2002;185(suppl 2):S138-S142. doi:10.1086/340203
25. Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol. 2002;40(1):27-33. doi:10.1016/S0735-1097 (02)01938-1
26. Ulich TR, del Castillo J, Ni RX, Bikhazi N. Hematologic interactions of endotoxin, tumor necrosis factor alpha (TNF alpha), interleukin 1, and adrenal hormones and the hematologic effects of TNF alpha in Corynebacterium parvum–primed rats. J Leukoc Biol. 1989;45(6):546-557. doi:10.1002/jlb.45.6.546
27. Ulich TR, del Castillo J, Ni RX, Bikhazi N, Calvin L. Mechanisms of tumor necrosis factor alpha–induced lymphopenia, neutropenia, and biphasic neutrophilia: a study of lymphocyte recirculation and hematologic interactions of TNF alpha with endogenous mediators of leukocyte trafficking. J Leukoc Biol. 1989;45(2):155-167. doi:10.1002/jlb.45.2.155
28. Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha–induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol. 1987;139(10):3406-3415. https://www.jimmunol.org/content/139/10/3406. Accessed October 23, 2019.
29. Malmejac J, Gross A. [Lymphopenia following an intravenous injection of adrenalin; application of adrenalin in the exploration of the adrenal and pituitary glands]. Alger Medicale. 1950;54(3):145-147.
30. Gordon AS. Some aspects of hormonal influences upon the leukocytes. Ann N Y Acad Sci. 1955;59(5): 907-927. doi:10.1111/j.1749-6632.1955.tb45990.x
31. Zidar DA, Mudd JC, Juchnowski S, et al. Altered maturation status and possible immune exhaustion of CD8 T lymphocytes in the peripheral blood of patients presenting with acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2016;36(2):389-397. doi:10.1161/ATVBAHA.115.306112
32. Al-Kindi SG, Attizzani GF, Decicco AE, et al. Lymphocyte counts are dynamic and associated with survival after transcatheter aortic valve replacement. Structural Heart. 2018;2(6):557-564. doi:10.1080/24748706. 2018.1522680
33. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
34. Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min Y-I, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169(1):20-29. doi:10.7326/M17-3011
35. Epping-Jordan JE, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. Lancet. 2005;366(9497):1667-1671. doi:10.1016/S0140-6736(05)67342-4
36. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337-3347. doi:10.1161/CIRCULATIONAHA.104.507996
37. Kearns A, Gordon J, Burdo TH, Qin X. HIV-1–associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol. 2017;69(25):3084-3098. doi:10.1016/j.jacc.2017.05.012
38. Wright K, Crowson CS, Gabriel SE. Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure. Heart Fail Clin. 2014;10(2):339-352. doi:10.1016/j.hfc.2013.10.003
39. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100-1112. doi:10.1161/CIRCULATIONAHA.117.033369
40. Wang HL, Zhou YM, Zhu GZ, Yang Z, Hua BJ. Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study. Clin Rheumatol. 2018;37(1):81-85. doi:10.1007/s10067-017-3676-8
41. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296. doi: 10.1056/NEJMoa062360
42. Le Campion A, Gagnerault M-C, Auffray C, et al. Lymphopenia-induced spontaneous T-cell proliferation as a cofactor for autoimmune disease development. Blood. 2009;114(9):1784-1793. doi:10.1182/blood-2008-12-192120
43. Freeman ML, Mudd JC, Shive CL, et al. CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection. Clin Infect Dis. 2016;62(3):392-396. doi:10.1093/cid/civ840
44. Toft P, Svendsen P, Tønnesen E, Rasmussen JW, Christensen NJ. Redistribution of lymphocytes after major surgical stress. Acta Anaesthesiol Scand. 1993;37(3):245-249. doi:10.1111/j.1399-6576.1993.tb03708.x
45. Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol. 2000;74(13): 6105-6116. doi:10.1128/JVI.74.13.6105-6116.2000
46. Nichols JE, Niles JA, Roberts NJ Jr. Human lymphocyte apoptosis after exposure to influenza A virus. J Virol. 2001;75(13):5921-5929. doi:10.1128/JVI.73.13.5921-5929.2001
47. Giovannini S, Onder G, Liperoti R, et al. Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals. J Am Geriatr Soc. 2011;59(9):1679-1685. doi: 10.1111/j.1532-5415.2011.03570.x
48. Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008;10(7):494-498. https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2008&month=07&page=494. Accessed October 23, 2019.
49. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22 (10):1668-1673. doi:10.1161/01.ATV.0000029781.31325.66
50. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
51. Al-Kindi SG, Kim CH, Morris SR, et al. Brief report: elevated red cell distribution width identifies elevated cardiovascular disease risk in patients with HIV infection. J Acquir Immune Defic Syndr. 2017;74(3):298-302. doi: 10.1097/QAI.0000000000001231
52. Duchnowski P, Szymański P, Orłowska-Baranowska E, Kuśmierczyk M, Hryniewiecki T. Raised red cell distribution width as a prognostic marker in aortic valve replacement surgery. Kardiol Pol. 2016;74(6):547-552. doi:10.5603/KP.a2015.0213
53. Felker GM, Allen LA, Pocock SJ, et al; CHARM Investigators. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50 (1):40-47. doi:10.1016/j.jacc.2007.02.067
54. Madu AJ, Ughasoro MD. Anaemia of chronic disease: an in-depth review. Med Princ Pract. 2017;26(1):1-9. doi: 10.1159/000452104
55. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443. doi:10. 1016/j.bbamcr.2012.01.014
56. Allen LA, Felker GM, Mehra MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010;16(3):230-238. doi:10.1016/j.cardfail.2009.11.003
57. Al-Kindi SG, Zidar DA, McComsey GA, Longenecker CT. Association of anisocytosis with markers of immune activation and exhaustion in treated HIV. Pathog Immun. 2017;2(1):138-150. doi:10.20411/pai.v2i1.199
58. Lorente L, Martín MM, Abreu-González P, et al. Red blood cell distribution width during the first week is associated with severity and mortality in septic patients. PLoS One. 2014;9(8):e105436. doi:10.1371/journal.pone. 0105436